S
Sight Diagnostics
Sight Diagnostics is a medical device company bringing affordable, accurate diagnostics to the point-of-care
About Sight Diagnostics
Sight Diagnostics, the company behind Sight OLO, operates in the healthcare technology market, providing innovative solutions for blood testing. The company's flagship product, Sight OLO, is a high-performance complete blood count (CBC) analyzer that delivers accurate results within minutes. This product is FDA 510(k) cleared for use in moderately complex laboratories, making it a reliable tool for healthcare providers.
Sight OLO's primary clients are healthcare practices that require quick and accurate blood test results. The device is easy to use and doesn't require calibration or maintenance, making it a practical choice for busy healthcare environments. It uses a small blood sample, either from a finger prick or venous draw, and processes the results in minutes. This quick turnaround time allows healthcare providers to make immediate treatment decisions, reducing patient anxiety and potentially improving health outcomes.
The business model of Sight Diagnostics is based on the sale of the Sight OLO device to healthcare providers. The company generates revenue from the sale of these devices, which are designed to streamline the workflow of healthcare practices and improve patient care.
Sight Diagnostics has been recognized for its innovative approach, being named one of the 2021 CNBC Disruptor 50 Companies, a 2021 Bronze Winner, and receiving an honorable mention in the 2021 World Changing Ideas Awards. It was also a quarterfinalist in the 2020 UCSF Digital Health Awards.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Bnei Brak, Israel
- Employees
- 66
- Open positions
- None listed
- Dealroom signal
- 64.4/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Testing, Data Analytics, Biotechnology, Medical Imaging, Core AI, Health Diagnostics, Tech for Hospitals and Clinics, Clinical Decision Support, Hard Tech, AI Applications
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2020 | $12M | $47M | OurCrowd | — |
| SERIES DOther financing | Jul 2020 | $71M | $284M | Clal Biotechnology Industries | — |
Growth signals
Latest recorded traffic for Sight Diagnostics is 1.1K monthly website visits, up 100% over the last three months. Sight Diagnostics's team declined 1.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
OurCrowd
Moshe Yanai
Series A5 investors entered at this stage
Innovation Endeavors
Clal Biotechnology Industries
Emery Capital
GEOC - China-Israel fund
New Alliance Capital
Series B and later4 investors entered at this stage
Longliv Ventures
GO Capital- SESteve Erick
- JIJack Nicklaus II
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sight Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sight Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.